Table 4.
Crude and adjusted regression models to estimate the association between the presence of adverse effects from vaccination with the fourth dose against COVID-19 and the variables of interest in adults over 40 years of age in Trujillo, Peru.
| 3d vs. No Event | 7d vs. No Event | 14d vs. No Event | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RRc | 95% CI | p-Value | RRa | 95% CI | p-Value | RRc | 95% CI | p-Value | RRa | 95% CI | p-Value | RRc | 95% CI | p-Value | RRa | 95% CI | p-Value | |
| Age (years) | ||||||||||||||||||
| <60 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| ≥60 | 0.32 | 0.18–0.59 | <0.001 | 0.29 | 0.15–0.53 | <0.001 | 0.37 | 0.17–0.80 | 0.011 | 0.43 | 0.19–0.98 | 0.044 | 0.43 | 0.16–1.12 | 0.084 | 0.54 | 0.17–1.65 | 0.279 |
| Sex | ||||||||||||||||||
| Female | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Male | 0.54 | 0.30–0.98 | 0.044 | 0.53 | 0.28–0.99 | 0.049 | 0.65 | 0.30–1.39 | 0.272 | 0.76 | 0.34–1.71 | 0.513 | 0.43 | 0.17–1.12 | 0.085 | 0.44 | 0.16–1.18 | 0.103 |
| vaccination scheme | ||||||||||||||||||
| Homologous | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Heterologous | 1.88 | 0.90–3.91 | 0.092 | 1.31 | 0.59–2.90 | 0.510 | 3.96 | 1.67–9.37 | 0.002 | 3.50 | 1.34–9.13 | 0.011 | 3.23 | 1.14–9.11 | 0.027 | 2.66 | 0.80–8.85 | 0.11 |
| BMI | ||||||||||||||||||
| Normal weight | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Overweight | 2.34 | 1.12–4.89 | 0.024 | 0.93 | 0.43–2.04 | 0.856 | 2.17 | 0.87–5.35 | 0.094 | 1.20 | 0.44–3.21 | 0.729 | 4.02 | 1.28–12.65 | 0.017 | 1.47 | 0.43–5.01 | 0.524 |
| Obesity | 1.16 | 0.58–2.32 | 0.674 | 0.77 | 0.33–1.79 | 0.546 | 0.96 | 0.38–2.42 | 0.932 | 0.81 | 0.27–2.41 | 0.700 | 1.39 | 0.40–4.89 | 0.605 | 1.31 | 0.33–5.23 | 0.708 |
| Previous infection by COVID-19 | ||||||||||||||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Yes | 1.54 | 0.79–3.03 | 0.207 | 1.26 | 0.63–2.52 | 0.516 | 1.58 | 0.69–3.63 | 0.284 | 1.23 | 0.52–2.90 | 0.633 | 0.95 | 0.31–2.86 | 0.922 | 0.79 | 0.25–2.51 | 0.690 |
| Simultaneous vaccination against influenza | ||||||||||||||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Yes | 2.35 | 0.89–6.19 | 0.084 | 2.88 | 1.07–7.74 | 0.036 | 1.84 | 0.57–5.88 | 0.306 | 2.27 | 0.69–7.52 | 0.178 | 0.82 | 0.15–4.52 | 0.817 | 0.85 | 0.14–5.03 | 0.856 |
| Presence of comorbidities | ||||||||||||||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||||||
| Yes | 1.35 | 0.58–3.18 | 0.487 | 1.63 | 0.69–3.84 | 0.264 | 2.19 | 0.80–5.93 | 0.124 | 3.12 | 1.11–8.76 | 0.031 | 1.22 | 0.33–4.61 | 0.769 | 1.63 | 0.40–6.69 | 0.501 |
| Last vaccine | ||||||||||||||||||
| mRNA-1273 (Moderna) | Ref. | Ref. | Ref. | |||||||||||||||
| BNT162b2 (Pfizer-BioNtech) | 0.42 | 0.18–0.96 | 0.041 | 0.18 | 0.04–0.89 | 0.035 | N.A. | |||||||||||
| Previous BBIBP-CorV | ||||||||||||||||||
| No | Ref. | Ref. | Ref. | |||||||||||||||
| Yes | 2.01 | 0.94–4.64 | 0.071 | 2.88 | 1.13–7.31 | 0.026 | 1.73 | 0.53–5.63 | 0.366 | |||||||||
RRc: crude relative risk; RRa: adjusted relative risk; CI: confidence interval; Ref: reference. N.A.: not available.